耐碳青霉烯类肠杆菌目细菌感染的治疗进展
Progress in the Treatment of Carbapenem-Resistant Enterobacterales Infections
摘要: 耐碳青霉烯类肠杆菌目细菌(CRE)已成为全球公共卫生领域的重大威胁，其高耐药性、强致病性及高致死率严重阻碍临床诊疗。近年来，针对此类感染治疗的方案不断丰富，从传统多黏菌素类的联合应用，到新型β-内酰胺类/β-内酰胺酶抑制剂复方制剂的临床推广，再到氟环素类与多黏菌素类联合方案的探索均取得了重要进展。本文结合近年国内外最新研究，梳理CRE感染的主流治疗方案，重点比较各类抗菌药物单药及联合用药的临床疗效、优势与局限，并展望未来研究方向，为临床感染个体化治疗提供理论参考。
Abstract: Carbapenem-Resistant Enterobacterales (CRE) have emerged as a major threat to the global public health. Their high drug resistance, strong pathogenicity, and high mortality rate have severely hindered clinical diagnosis and treatment. In recent years, the therapeutic regimens for such infections have been continuously enriched. Significant progress has been made from the combined application of traditional polymyxins, the clinical promotion of new β-lactam/β-lactamase inhibitor combinations, to the exploration of combined regimens of fluorocyclines and polymyxins. Based on the new research findings at home and abroad in recent years, this article sorts out the mainstream therapeutic regimens for CRE infections, focuses on comparing the clinical efficacy, advantages and limitations of various antibacterial drugs in both monotherapy and combined medication, and looks forward to the future research directions. It aims to provide a theoretical reference for the clinical individualized treatment of CRE infections.
文章引用：尚李莎, 牛司强. 耐碳青霉烯类肠杆菌目细菌感染的治疗进展[J]. 临床医学进展, 2026, 16(6): 331-337. https://doi.org/10.12677/acm.2026.1662225

参考文献

[1] Tompkins, K. and van Duin, D. (2021) Treatment for Carbapenem-Resistant Enterobacterales Infections: Recent Advances and Future Directions. European Journal of Clinical Microbiology & Infectious Diseases, 40, 2053-2068. [Google Scholar] [CrossRef] [PubMed]
[2] Ma, J., Song, X., Li, M., Yu, Z., Cheng, W., Yu, Z., et al. (2023) Global Spread of Carbapenem-Resistant Enterobacteriaceae: Epidemiological Features, Resistance Mechanisms, Detection and Therapy. Microbiological Research, 266, Article 127249. [Google Scholar] [CrossRef] [PubMed]
[3] Li, Y., Mai, Y., Liu, Y. and Jiang, Y. (2025) Epidemiological Characteristics and Carbapenemase Analysis of Carbapenem-Resistant Enterobacterales Isolates in a Teaching Hospital in Guangzhou, China. Infection and Drug Resistance, 18, 2105-2117. [Google Scholar] [CrossRef] [PubMed]
[4] Dossouvi, K.M., Sambe Ba, B., Lo, G., Sellera, F.P., Furlan, J.P.R., Culot, A., et al. (2025) Clinical Carbapenem-Resistant Enterobacterales in a University Hospital in Dakar, Senegal: Genomic Insights into Enterobacter Hormaechei ST182 Strains Carrying blaNDM-5 and blaOXA-48 Genes. Microbiology Spectrum, 13, e00780-25. [Google Scholar] [CrossRef] 
[5] Kanj, S.S., Bassetti, M., Kiratisin, P., Rodrigues, C., Villegas, M.V., Yu, Y., et al. (2022) Clinical Data from Studies Involving Novel Antibiotics to Treat Multidrug-Resistant Gram-Negative Bacterial Infections. International Journal of Antimicrobial Agents, 60, Article 106633. [Google Scholar] [CrossRef] [PubMed]
[6] Mackow, N.A. and van Duin, D. (2024) Reviewing Novel Treatment Options for Carbapenem-Resistant Enterobacterales. Expert Review of Anti-Infective Therapy, 22, 71-85. [Google Scholar] [CrossRef] [PubMed]
[7] 曾玫, 夏君, 宗志勇, 等. 碳青霉烯类耐药革兰阴性菌感染的诊断、治疗及防控指南[J]. 中国感染与化疗杂志, 2024, 24(2): 135-151.
[8] Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J. and Bonomo, R.A. (2024) Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clinical Infectious Diseases, 2024, ciae403. [Google Scholar] [CrossRef] [PubMed]
[9] 刘婷婷, 谢小芳, 杜鸿. 耐碳青霉烯类肠杆菌目细菌药敏表型与产碳青霉烯酶酶型的相关性分析[J]. 中国抗菌药物杂志, 2024, 49(10): 1081-1088.
[10] Shields, R.K., Chen, L., Cheng, S., Chavda, K.D., Press, E.G., Snyder, A., et al. (2017) Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infections. Antimicrobial Agents and Chemotherapy, 61, 1-11. [Google Scholar] [CrossRef] [PubMed]
[11] Marino, A., Maraolo, A.E., Mazzitelli, M., Oliva, A., Geremia, N., De Vito, A., et al. (2025) Head-to-Head: Meropenem/Vaborbactam versus Ceftazidime/Avibactam in ICUs Patients with KPC-Producing K. Pneumoniae Infections—Results from a Retrospective Multicentre Study. Infection, 53, 2645-2658. [Google Scholar] [CrossRef] [PubMed]
[12] Huang, P.Y., Hsu, C.K., Tang, H.J., et al. (2024) Eravacycline: A Comprehensive Review of in Vitro Activity, Clinical Efficacy, and Real-World Applications. Expert Review of Anti-Infective Therapy, 22, 387-398. [Google Scholar] [CrossRef] [PubMed]
[13] LaPlante, K.L., Dhand, A., Wright, K. and Lauterio, M. (2022) Re-Establishing the Utility of Tetracycline-Class Antibiotics for Current Challenges with Antibiotic Resistance. Annals of Medicine, 54, 1686-1700. [Google Scholar] [CrossRef] [PubMed]
[14] Zhao, X., Wang, J., Deng, X., Shi, M., Song, S., Zhao, S., et al. (2026) Eravacycline Monotherapy and Combination Therapy against KPC-2-and NDM-1-Co-Producing Klebsiella Pneumoniae: In Vitro and in Vivo Activity Analysis. Frontiers in Microbiology, 17, Article 1802577. [Google Scholar] [CrossRef] 
[15] 查娴, 陈大宇, 邵华. 替加环素和多黏菌素B治疗重症患者耐碳青霉烯类肠杆菌科细菌肺炎的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2024, 29(2): 154-163.
[16] Sheu, C.C., Chang, Y.T., Lin, S.Y., et al. (2019) Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Frontiers in Microbiology, 10, Article 80. [Google Scholar] [CrossRef] [PubMed]
[17] Ataman, M. and Çelik, B.Ö. (2025) Investigation of the in Vitro Antimicrobial Activity of Eravacycline Alone and in Combination with Various Antibiotics against MDR Acinetobacter Baumanni Strains. BMC Microbiology, 25, Article No. 167. [Google Scholar] [CrossRef] [PubMed]
[18] Wu, Y., Yu, W., Chu, X., Zhang, J., Jia, P., Liu, X., et al. (2024) Effect of Ceftazidime-Avibactam Combined with Different Antimicrobials against Carbapenem-Resistant Klebsiella pneumoniae. Microbiology Spectrum, 12, e10724. [Google Scholar] [CrossRef] [PubMed]
[19] Sader, H.S., Kimbrough, J.H., Winkler, M.L., Castanheira, M. and Mendes, R.E. (2025) Aztreonam/Avibactam Activity against Enterobacterales from European Medical Centres: Summary of 5 Years of Surveillance Prior to Approval for Clinical Use (2019-2023). Journal of Antimicrobial Chemotherapy, 80, 2070-2079. [Google Scholar] [CrossRef] [PubMed]
[20] Huespe, I.A., Huaier, A.E., Sanchez, M., et al. (2025) Mortality of Metallo-β-Lactamase-Producing Enterobacterales Bacteremias with Combined Ceftazidime-Avibactam plus Aztreonam vs. Other Active Antibiotics: A Multicenter Target Trial Emulation. The Lancet Regional Health, 49, Article 101175.
[21] Keck, J.M., Dare, R.K., Saccente, M., Vyas, K.S. and Thompson, R.N. (2025) Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter Cloacae. Antibiotics, 14, Article 1109. [Google Scholar] [CrossRef] 
[22] Hölsken, O., Sponheuer, K., Weber, F., Martens-Lobenhoffer, J., Bode-Böger, S.M., Kloft, C., et al. (2024) First Clinical Application of Aztreonam-Avibactam in Treating Carbapenem-Resistant Enterobacterales: Insights from Therapeutic Drug Monitoring and Pharmacokinetic Simulations. Journal of Personalized Medicine, 14, Article 1135. [Google Scholar] [CrossRef] [PubMed]
[23] Huang, Y.S., Yang, J.L., Wang, J.T., et al. (2024) Evaluation of the Synergistic Effect of Eravacycline and Tigecycline against Carbapenemase-Producing Carbapenem-Resistant Klebsiella Pneumoniae. Journal of Infection and Public Health, 17, 929-937. [Google Scholar] [CrossRef] [PubMed]
[24] Nang, S.C., Azad, M.A.K., Velkov, T., Zhou, Q. and Li, J. (2021) Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacological Reviews, 73, 679-728. [Google Scholar] [CrossRef] [PubMed]
[25] González-Gómez, I., Ruíz-Carrascoso, G. and Herruzo-Cabrera, R. (2025) A Decade of Epidemiology and Incidence of Carbapenemase-Producing Bacteria in a Tertiary Hospital in Southern Europe. Infection Prevention in Practice, 7, Article 100469. [Google Scholar] [CrossRef] [PubMed]
[26] Tiseo, G., Galfo, V. and Falcone, M. (2025) How I Manage Patients with New Delhi Metallo-Beta-Lactamase and OXA-48-Producing Enterobacterales Infections: A Practical Approach. Current Opinion in Infectious Diseases, 38, 588-597. [Google Scholar] [CrossRef] 
[27] Jayarajan, D., Mulavagili, S. and Vijayasimha, M. (2026) Commentary: CRISPR-Cas Systems against Carbapenem Resistance from Proof-of-Concept to Clinical Translation. Frontiers in Microbiology, 17, Article 1773181. [Google Scholar] [CrossRef] 
[28] Imanaka, M., Yamashita, W., Ojima, S., Azam, A.H., Kataoka, M., Suzuki, T., et al. (2025) Isolation and Characterization of Bacteriophages for Carbapenem Resistant Enterobacter Cloacae Complex Strains. Scientific Reports, 15, Article No. 38914. [Google Scholar] [CrossRef] 
[29] Hairsine, B., Leire, E., Rostam, H.M., Kristian, S.A., Rhodes, E., Johnson, A., et al. (2025) Harnessing Endogenous Anti-Glycan Antibodies Using a Novel, Bifunctional Immunotherapy to Treat Gram-Negative Bacterial Infections. The Journal of Immunology, 214, 1617-1629. [Google Scholar] [CrossRef] [PubMed]
[30] Shin, T.G. (2024) Assessment of Organ Failure in Sepsis Patients in the Emergency Department: Clinical Evaluation, Sequential Organ Failure Assessment (SOFA) Score, and Future Perspectives. Clinical and Experimental Emergency Medicine, 11, 327-330. [Google Scholar] [CrossRef] [PubMed]
[31] Kao, K. and Alocilja, E.C. (2025) A Review of the Diagnostic Approaches for the Detection of Antimicrobial Resistance, Including the Role of Biosensors in Detecting Carbapenem Resistance Genes. Genes, 16, Article 794. [Google Scholar] [CrossRef] [PubMed]
[32] Leroux, P., Bornet, C., Bolla, J. and Cohen, A. (2025) Challenges of Carbapenem-Resistant Enterobacteriaceae in the Development of New Β-Lactamase Inhibitors and Antibiotics. Antibiotics, 14, Article 587. [Google Scholar] [CrossRef] [PubMed]
[33] 江琦, 贾枕枕, 王玲玲, 等. 耐碳青霉烯类肠杆菌科细菌感染治疗进展[J]. 医药导报, 2024, 43(4): 581-587.
[34] 宋羽希, 李福祥. 耐碳青霉烯类肠杆菌科细菌感染治疗策略[J]. 西南国防医药, 2019, 29(11): 1170-1173.
[35] Sangiorgio, G., Calvo, M. and Stefani, S. (2025) Aztreonam and Avibactam Combination Therapy for Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review. Clinical Microbiology and Infection, 31, 971-978. [Google Scholar] [CrossRef] [PubMed]

为你推荐